GSK Completes Retrofit of Maryland Facility

October 4, 2019

GSK invested $139 million to its Rockville, MD site to support demand for Benlysta.

GSK marked the completion of construction of a biopharmaceutical manufacturing facility at its Rockville, MD site with a ceremony on Oct. 3, 2019. The $139 million investment into the Rockville site, originally announced in May 2017, will support the growing demand for Benlysta (belimumab), GSK’s treatment for patients with systemic lupus erythematosus (SLE).

The investment was used to retrofit an existing facility at the Rockville manufacturing site and covered demolition of existing suites, engineering, installation, and validation of equipment. 

The expansion increased manufacturing capacity at the site by 50% and created 100 new jobs, bringing the total number of GSK jobs in the Rockville, MD area to approximately 1000.

Benlysta was launched in 2011 and in April 2019, FDA also approved its expanded use for the treatment of patients aged five years and older with active, autoantibody-positive SLE who are receiving standard therapy.

Source: GSK